Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 9Endocrine 9Plasma cell 2Other hematologic neoplasm 2Gastrointestinal 2CNS 2Thoracic 1Sarcoma 1Myeloid 1Lymphoid 1Gynecologic 1

Conditions

Colorectal Neoplasms 20Pancreatic Neoplasms 11Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Rectal Neoplasms 5Colonic Neoplasms 5Thyroid Neoplasms 4Multiple Myeloma 4Cholangiocarcinoma 4Biliary Tract Neoplasms 4Neoplasm Metastasis 3Melanoma 3Hematologic Neoplasms 3Glioma 3Breast Neoplasms 3Bile Duct Neoplasms 3Triple Negative Breast Neoplasms 2Thyroid Carcinoma, Anaplastic 2Prostatic Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Gastrointestinal Stromal Tumors 2Carcinoma, Hepatocellular 2Adenocarcinoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Thrombocytosis 1Stomach Neoplasms 1

Interventions

trametinib 2dabrafenib 2Trastuzumab 2zimberelimab 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tislelizumab 1tipifarnib 1surufatinib 1sargramostim 1mercaptoundecahydrododecaborate 1cobimetinib 1aldesleukin 1Vemurafenib 1Tamoxifen 1Radiotherapy 1PLX8394 1Interleukin-12 Subunit p35 1Interleukin-12 1Doxorubicin 1Cisplatin 14-boronophenylalanine-fructose 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Thyroid Carcinoma, Anaplastic × trametinib × Gastrointestinal × Clear all
NCT07440290 2026-02-27

DETERMINE

Cancer Research UK

Phase 2/3 Not yet recruiting
30 enrolled
CNSEndocrineGastrointestinalGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Glioma, Histiocytosis, Langerhans-Cell, Laryngeal Neoplasms, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡